Tonix Pharmaceuticals TNXP Stock News

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is running for the top in the market this morning, trading on gains of aroun 50% early on. The gains come after the company announced that it entered into a COVID-19-related partnership. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

TNXP Stock Rockets On COVID-19 Collaboration

In the press release, Tonix Pharmaceuticals said that it entered into a research and collaboration agreement with Columbia University. The collaboration surrounds the study of immune response to COVID-19 in healthy volunteers who recovered from COVID-19 and were asymptomatic.

In particular, the two will work on T cell and antibody responses to the coronavirus at the cellular level. TNXP said that this will include human monoclonal antibodies and anti-idiotypes.

This research is being done in order to fill gaps in the understanding of the immune response to COVID-19, and to provide a foundation upon which to target vaccines and therapeutic options that are appropriate to individuals through precision medicine.

In a statement, Seth Lederman, M.D., President and CEO at TNXP, had the following to offer:

We expect that more than one COVID-19 vaccine will ultimately be approved by the Food and Drug Administration (FDA), and a challenge for future research will be to determine which vaccine is appropriate for each individual. Data from this collaboration will provide a roadmap and tools to potentially guide these recommendations.

This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix’s TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can designed which will be tailored to individuals by precision medicine. We are excited to work with our collaborators at Columbia University on these precision medicine technologies and also to potentially develop new monoclonal antibody therapeutics.

This News Is Huge

At the end of the day, we thought that the COVID-19 pandemic was improving, leading to the reopening of the United States economy. However, as people started to venture out of their homes we’re seeing vast increases in case counts on a daily basis.

The bottom line is that COVID-19 is here to stay until we find vaccines and treatments to combat it. That’s where Tonix Pharmaceuticals comes in.

The company’s work to develop a precision medicine platform surrounding COVID-19 vaccines and treatments is overwhelmingly important. As mentioned in the press release, this research has the potential to provide the foundation for incredibly valuable tools in the fight of the pandemic. As such, TNXP stock is one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.